Test Price
2,000 AED✅ Home Collection Available
Amikacin Therapeutic Drug Monitoring (TDM) Test in Dubai – 2000 AED
Executive Summary & Core Metrics
- Diagnostic Precision: Quantitative immunoassay (PETINIA) with intra-assay CV <4% – validated per ISO 9001:2015.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM to 11 PM.
- Clinical Guidance: Post-result telephonic consultation included to interpret trough/peak levels.
- Insurance Support: Direct coverage verification via WhatsApp +971545488731.
Test Overview & Methodology
The Amikacin Therapeutic Drug Monitoring (TDM) test quantifies serum drug concentrations to optimise dosing and minimise nephrotoxicity or ototoxicity in severe Gram‑negative infections. Our DHA‑accredited immunoassay delivers precise trough and peak measurements, guiding clinicians to maintain therapeutic efficacy while avoiding toxicity.
| Parameter | Our Advanced Test | Conventional Alternative |
|---|---|---|
| Analytical Method | Quantitative Immunoassay (PETINIA) – intra‑assay CV <4% | Non‑specific bioassay or outdated colorimetry |
| Sample Requirements | 1 mL serum (red‑top tube), refrigerated/frozen transport | Larger volumes, shorter stability |
| Turnaround Time | Report in 2–3 weeks* (batch‑processed in international reference lab) | Often >4 weeks with limited traceability |
*Samples collected by the 7th of the month; report delivered via secure portal within 2‑3 weeks.
Physician Insight & Safety Protocols
– Dr. Ajay Singh, General Practitioner (DHA 36234132)
⚠️ Critical Safety Advisory
- Do not alter or discontinue prescribed amikacin without consulting your treating physician. Abrupt cessation may lead to resistant infections or clinical deterioration.
- Exclusion Criteria for Home Collection: Refusal to sign the mandatory Test Send Out Consent Form (Form 35); inability to maintain cold‑chain during transport; known coagulopathy without medical clearance.
- Emergency Red Flags: Seek immediate care if you experience new‑onset tinnitus, vertigo, oliguria, or rash after sampling – these may indicate ototoxicity or anaphylaxis.
Patient FAQ & Clinical Guidance
1. What does the amikacin test tell my doctor about my treatment?
The amikacin test quantifies the drug concentration in your blood at critical trough (lowest) and peak (highest) times, enabling your nephrologist or neonatologist to adjust the dose precisely – preventing toxic accumulation while ensuring the antibiotic eliminates the bacteria causing your serious infection. This monitoring is especially important for patients with fluctuating kidney function.
2. When exactly should I collect the blood sample?
Sample timing is crucial: the trough sample is drawn immediately before the next dose, and the peak sample 30–60 minutes after IV infusion or 60 minutes after intramuscular injection. Your physician will provide exact timings. Never alter the schedule without medical guidance – improper timing leads to inaccurate dose adjustments.
3. Why does the result take 2–3 weeks and what happens during that time?
Your sample is sent to a specialised international reference laboratory (ISO 9001:2015 certified). The 2–3 week window allows for cold‑chain shipment, batch immunoassay analysis, and rigorous two‑step quality control review before your physician receives the traceable report. During this period, your clinical team continues to monitor your progress and may make interim adjustments based on clinical signs.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your personal health information is processed solely for clinical care and secure data handling.
Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Amikacin Therapeutic Drug Monitoring (TDM) |
| Price (AED) | 2,000 |
| Turnaround Time | 2–3 weeks (batch‑processed) |
| Sample Type / Matrix | Serum (red‑top tube), 1 mL |
| Methodology Used | Quantitative Immunoassay (PETINIA) |
| ICD-10-CM Code | Z51.81 (Encounter for therapeutic drug monitoring) |
| LOINC Code | 3392-1 (Amikacin [Mass/volume] in Serum or Plasma) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians